HER-Vaxx Re-Formulation Shows Dramatic Ten-Fold Increase in Antibodies and Early Onset of Response
22-Apr-2015 -
Imugene Limited, a clinical stage immuno-oncology company developing HER-2 positive gastric and breast cancer immunotherapies, announces that Imugene’s lead candidate HER-Vaxx has demonstrated a powerful increase in the production of cancer fighting antibodies in preclinical animal model testing. ...
antibodies
cancer
cancer immunotherapies